Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS.
Objective: To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications.
Results: Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35-53) and median PAPS disease duration of 13 years (8-19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients.
Conclusion: ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09612033211033978 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome.
Front Immunol
September 2025
Department of Nephrology, The First Affiliated Hospital, Dalian Medical University, Dalian, China.
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder characterized by arterial and venous thrombosis, pregnancy-related complications, and persistent antiphospholipid antibodies. These manifestations pose significant risks to patient health and reproductive outcomes. Initially regarded as a manifestation of systemic lupus erythematosus (SLE), APS exhibits a close epidemiological association with SLE, occurring at significantly higher incidence in SLE patients.
View Article and Find Full Text PDFChallenges in the Diagnosis of Systemic Lupus Erythematosus.
Clin Med (Lond)
September 2025
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address:
Systemic lupus erythematosus (SLE) is a life-long, complex, multi-system, autoimmune condition which can occur at any age, most commonly in female adults in their reproductive years. Diagnosis is often delayed with reported time from symptom onset to diagnosis as long as 6 years. Delayed diagnosis can result in irreversible organ damage, acute hospital admission, poor health-related outcomes and increased risk of mortality.
View Article and Find Full Text PDFIntroduction: Systemic lupus erythematosus (SLE) is an autoimmune disease, more prevalent among African-American women, often associated with severe manifestations such as lupus nephritis and neuropsychiatric lupus. Both conditions contribute significantly to morbidity and mortality, though lupus nephritis is more commonly linked to direct disease-related deaths. Mortality can also result from other severe disease manifestations or treatment-related complications.
View Article and Find Full Text PDFPrevalence and incidence of systemic lupus erythematosus in Thailand based on national health data.
Lupus Sci Med
September 2025
Department of Medicine, Khon Kaen University, Nai Mueang, Khon Kaen, Thailand
Background: SLE is an autoimmune disease that varies across ethnic populations and the regions that cause economic burdens, but nationwide epidemiological data for Thailand are lacking.
Objective: To estimate the incidence and prevalence of SLE in Thailand between 2017 and 2020.
Methods: A retrospective cohort study used the Information and Communication Technology Center, Ministry of Public Health, covering all major healthcare insurance systems (nearly 90% of hospitals, about 80% of the Thai population).
Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study.
RMD Open
September 2025
Department of Rheumatology, Oslo University Hospital, Oslo, Norway.
Objective: This population-based study aimed to determine timing and incidence of arterial and venous thromboembolic events (TE) and antiphospholipid syndrome (APS) relative to systemic lupus erythematosus (SLE) onset and assess relationships between TE, APS and anti-phospholipid antibodies (aPL) during follow-up.
Methods: We included all medical-record confirmed new-onset SLE patients in Southeast Norway (population 2.9 million) 2000-2017 who fulfilled the 2019 European Alliance of Rheumatology Associations/American College of Rheumatology classification criteria.